Skip to content

An exploratory study of antidepressant treatment using ketamine for treatment-resistant depression

An exploratory study of antidepressant treatment using ketamine for treatment-resistant depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012239
Enrollment
Unknown
Registered
2017-05-26
Start date
2017-08-10
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

ketamine:infusion of ketamine(0.5mg/kg)

Sponsors

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Male or female patients, 18-65 years of age; (2) Treatment-resistant depression that meet the DSM-5 diagnostic criteria, including unipolar and bipolar depression: patients were treated ineffectively by two kinds of antidepressants with sufficient dosage and full period course of treatment. Sufficient dosage means the maximum doses of more than two-thirds (equal to imipramine doses of 150~200mg/d), full period of treatment refers to adequate treatment for more than 4 weeks. Patients who are adsorbed in chronic depression must be treated more than 8 weeks. Ineffectiveness means score-reducing rate of Hamilton Depression Scale < 30%; or with apparent suicidal ideation as measured by the Beck Scale for?Suicide?Ideation; (3) Scores of Hamilton Depression Scale must over 17 when participants join in this study initially; (4) Participants must have junior middle school and above years of schooling; (5) Each participant must join in the study voluntarily and sign an informed consent.

Exclusion criteria

Exclusion criteria: (1) Other major psychiatric disorders that meet the DSM-5 diagnostic criteria include organic mental disorders, alcohol dependence, drug dependence/abuse, schizophrenia, etc; (2) Currently, there are serious and unstable somatic diseases such as diabetes, thyroid disease, hypertension, heart disease and narrow-angle glaucoma, etc; (3) A history of neurological diseases such as epilepsy and dementia; (4) Negative result on urotoxicological screening; (5) Women who are at the stage of pre-pregnancy, pregnancy or lataction; (6) Disobedient patients.

Design outcomes

Primary

MeasureTime frame
efficacy;

Secondary

MeasureTime frame
cognitive function;

Countries

China

Contacts

Public ContactNing Yuping

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital)

ningjeny@126.com+86 020-81268211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026